###begin article-title 0
Unique Bisphenol A Transcriptome in Prostate Cancer: Novel Effects on ERbeta Expression That Correspond to Androgen Receptor Mutation Status
###end article-title 0
###begin p 1
The authors declare they have no competing financial interests.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
Prostatic adenocarcinomas are dependent on androgen receptor (AR) activity for growth and progression, and therapy for disseminated disease depends on ablation of AR activity. Recurrent tumors ultimately arise wherein AR has been re-activated. One mechanism of AR restoration is via somatic mutation, wherein cells containing mutant receptors become susceptible to activation by alternative ligands, including bisphenol A (BPA). In tumors with specific AR mutations, BPA promotes therapeutic bypass, suggesting significant negative impact to the clinical management of prostate cancer.
###end p 3
###begin title 4
Objective
###end title 4
###begin p 5
Our goal was to determine the mechanism of BPA action in cancer cells carrying BPA-responsive AR mutants.
###end p 5
###begin title 6
Methods
###end title 6
###begin p 7
The molecular signature of BPA activity in prostate cancer cells harboring mutant AR was delineated via genetic microarray analysis. Specificity of BPA action was assessed by comparison with the molecular signature elicited by dihydrotestosterone (DHT).
###end p 7
###begin title 8
Results
###end title 8
###begin p 9
BPA and DHT elicited distinct transcriptional signatures in prostate cancer cells expressing the BPA-responsive mutant AR-T877A. BPA dramatically attenuated estrogen receptor beta (ERbeta) expression; this finding was specific to prostate tumor cells in which BPA induces cellular proliferation.
###end p 9
###begin title 10
Conclusions
###end title 10
###begin p 11
###xml 546 551 <span type="species:ncbi:9606">human</span>
BPA induces a distinct gene expression signature in prostate cancer cells expressing somatic AR mutation, and a major molecular consequence of BPA action is down-regulation of ERbeta. Since ERbeta functions to antagonize AR function and AR-dependent proliferation, these findings reveal a novel mechanism by which BPA likely regulates cellular proliferation. Future investigation directed at dissecting the importance of ERbeta in the proliferative response to BPA will establish the contribution of this event to adverse effects associated with human exposure.
###end p 11
###begin p 12
###xml 399 410 399 410 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b13-ehp0115-001646">Henley 2006</xref>
###xml 412 432 412 432 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b63-ehp0115-001646">Welshons et al. 2003</xref>
###xml 804 820 804 820 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b18-ehp0115-001646">Huff et al. 1996</xref>
###xml 139 144 <span type="species:ncbi:9606">human</span>
###xml 512 518 <span type="species:ncbi:9606">humans</span>
###xml 619 625 <span type="species:ncbi:9606">humans</span>
Accruing evidence indicates that exposure to environmental compounds that affect the function of the endocrine system may adversely impact human health. These substances deemed "endocrine disrupting compounds," or EDCs, are agents that disrupt or enhance known regulatory functions of the endocrine system and function through multiple mechanisms, including alteration of hormone receptor function (Henley 2006; Welshons et al. 2003). While mechanisms by which these effects occur and the level of risk posed to humans have yet to be fully elucidated, the biological significance of EDC exposure can be significant. In humans, a putative link has been established between increased abundance of estrogenic EDCs in the environment and both rising hormone-dependent cancer incidence and reduced fertility (Huff et al. 1996). Thus, recent investigations have placed particular emphasis on delineating the consequence of estrogenic EDC exposure on reproductive tissues.
###end p 12
###begin p 13
###xml 134 155 134 155 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b66-ehp0115-001646">Wetherill et al. 2002</xref>
###xml 157 161 157 161 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b64-ehp0115-001646">2005</xref>
###xml 163 167 163 167 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b65-ehp0115-001646">2006</xref>
###xml 318 338 318 338 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b63-ehp0115-001646">Welshons et al. 2003</xref>
###xml 516 535 516 535 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b4-ehp0115-001646">Calafat et al. 2005</xref>
###xml 629 651 629 651 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b62-ehp0115-001646">Welshons et al. (2006)</xref>
###xml 807 825 800 818 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b27-ehp0115-001646">Kuiper et al. 1997</xref>
###xml 925 948 918 941 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b14-ehp0115-001646">Hess-Wilson et al. 2006</xref>
###xml 950 967 943 960 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b42-ehp0115-001646">Olsen et al. 2003</xref>
###xml 1228 1247 1221 1240 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b3-ehp0115-001646">Ascenzi et al. 2006</xref>
###xml 1249 1269 1242 1262 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b48-ehp0115-001646">Shang and Brown 2002</xref>
###xml 1491 1512 1484 1505 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b66-ehp0115-001646">Wetherill et al. 2002</xref>
###xml 1514 1518 1507 1511 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b64-ehp0115-001646">2005</xref>
###xml 1520 1524 1513 1517 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b65-ehp0115-001646">2006</xref>
One such agent, 4,4'-isopropylidene-2-diphenol (bisphenol A, BPA), has been identified as a mitogen for a subset of prostate cancers (Wetherill et al. 2002, 2005, 2006). BPA is a nonplaner plasticizer, which is leached in microgram quantities from polycarbonate plastics and epoxy resins into food and water supplies (Welshons et al. 2003). More than 800 million kilograms of this compound are generated annually in the United States, and up to 95% of adults in the United States have detectable BPA in their urine (Calafat et al. 2005), with adult serum concentrations reported to range in nanomolar concentrations [reviewed by Welshons et al. (2006)]. BPA is known to harbor estrogenic activity; this compound is a weak agonist of both estrogen receptor alpha and beta (ERalpha and ERbeta, respectively) (Kuiper et al. 1997) and is capable of stimulating moderate estrogen-independent proliferation in breast cancer cells (Hess-Wilson et al. 2006; Olsen et al. 2003). The ERs are members of the steroid hormone nuclear receptor family of transcription factors, which are activated by specific steroid hormones and control numerous molecular pathways in hormone responsive tissues, including differentiation and proliferation (Ascenzi et al. 2006; Shang and Brown 2002). Although these reports highlighted a potentially influential role of BPA on ER activity in breast cancer, recent studies reveal BPA as an agonist for mutant androgen receptor (AR) activity in recurrent prostate cancer (Wetherill et al. 2002, 2005, 2006).
###end p 13
###begin p 14
###xml 94 120 94 120 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b56-ehp0115-001646">Trapman and Brinkmann 1996</xref>
###xml 389 404 389 404 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b32-ehp0115-001646">Lee et al. 1995</xref>
###xml 750 760 750 760 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b26-ehp0115-001646">Klotz 2000</xref>
###xml 762 778 762 778 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b45-ehp0115-001646">Reid et al. 1999</xref>
###xml 968 992 968 992 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b11-ehp0115-001646">Feldman and Feldman 2001</xref>
###xml 1226 1244 1226 1244 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b53-ehp0115-001646">Suzuki et al. 1993</xref>
###xml 1246 1269 1246 1269 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b59-ehp0115-001646">Veldscholte et al. 1990</xref>
###xml 1271 1276 1271 1276 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b57-ehp0115-001646">1992a</xref>
###xml 1278 1283 1278 1283 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b58-ehp0115-001646">1992b</xref>
###xml 1285 1301 1285 1301 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b69-ehp0115-001646">Zhao et al. 2000</xref>
###xml 1446 1467 1446 1467 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b66-ehp0115-001646">Wetherill et al. 2002</xref>
###xml 1469 1473 1469 1473 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b64-ehp0115-001646">2005</xref>
###xml 1661 1664 1661 1664 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PSA</italic>
###xml 2067 2074 2067 2074 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 2183 2204 2183 2204 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b65-ehp0115-001646">Wetherill et al. 2006</xref>
###xml 1226 1232 <span type="species:ncbi:8164">Suzuki</span>
Prostatic adenocarcinomas are uniquely dependent on AR activity for growth and proliferation (Trapman and Brinkmann 1996). In prostate cancer cells, androgen [testosterone or dihydrotestosterone (DHT) binding activates the receptor to bind DNA at androgen-responsive elements (AREs), recruit co-activators, and initiate a program of gene transcription that induces cellular proliferation (Lee et al. 1995). Given the reliance of prostate cancer cells on this signal, nullification of AR activity is the first line of therapeutic intervention for disseminated disease, as achieved through either ligand depletion (androgen ablation strategies) or through the use of direct AR antagonists that prevent formation of active AR transcriptional complexes (Klotz 2000; Reid et al. 1999). Although these strategies are initially effective at inducing cell death or cell cycle arrest, recurrent tumors arise within a median of 2-3 years, wherein AR activity has been restored (Feldman and Feldman 2001). One mechanism of AR reactivation is somatic mutation of the AR (estimated to occur in 8-25% of recurrent tumors), where specific mutations of the ligand binding domain render the receptor responsive to an expanded host of ligands (Suzuki et al. 1993; Veldscholte et al. 1990, 1992a, 1992b; Zhao et al. 2000). Remarkably, it has been shown that one of the most common tumor-derived mutant forms of the AR, AR-T877A, is responsive to activation by BPA (Wetherill et al. 2002, 2005). Specifically, it was shown that at environmentally relevant levels of BPA (1 nM), this agent is capable of binding and activating the mutant receptor to induce endogenous expression of PSA (prostate specific antigen, a known direct AR target), which is used clinically to monitor prostate cancer development and progression. In cancer cells that express this mutant, low-level BPA exposure induced androgen-independent cellular proliferation, thereby indicating that in the context of AR-T877A, BPA exposure could potentially reduce therapeutic efficacy. This concept was recently validated in vivo, wherein BPA accelerated tumor growth after androgen ablation and significantly reduced PSA doubling times (Wetherill et al. 2006). Thus, there is significant evidence that BPA can bolster AR-T877A activity and as a result potentially alter the course of therapeutic response in prostate cancer.
###end p 14
###begin p 15
###xml 403 424 403 424 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b66-ehp0115-001646">Wetherill et al. 2002</xref>
###xml 426 430 426 430 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b64-ehp0115-001646">2005</xref>
###xml 572 580 572 580 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 1055 1076 1048 1069 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b66-ehp0115-001646">Wetherill et al. 2002</xref>
###xml 804 809 <span type="species:ncbi:9606">human</span>
Given the potent effects of BPA on mutant AR activation and prostate cancer progression, it is imperative to determine the molecular underpinning of BPA action. There are differences in prostatic cellular response to BPA compared with DHT, including magnitude of proliferative response, distinctions in ligand binding, and different ligand-induced kinetics of AR recruitment to gene regulatory regions (Wetherill et al. 2002, 2005). Moreover, it is known that differential ligands dictate target gene specificity with regard to the nuclear receptors. Although substantial in vitro analyses have revealed the direct binding to and activation of mutant ARs by BPA, it is also well documented that BPA can activate ERalpha and ERbeta, which are expressed in several prostate cancer cell lines [e.g., LNCaP (human prostatic adenocarcinoma cell line)]. However, the BPA-induced cellular proliferation is dependent on AR activation, as blocking of AR function (using the specific AR antagonist, Casodex) reversed all effects of BPA on tumor cell proliferation (Wetherill et al. 2002). Therefore, it is believed that the adverse proliferative effect of BPA is directly through the AR. In our present study, only the proliferation-inducing dose of BPA (1 nM) was used for analysis.
###end p 15
###begin p 16
###xml 410 427 410 427 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b8-ehp0115-001646">Davis et al. 2003</xref>
###xml 429 447 429 447 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b37-ehp0115-001646">Matias et al. 2000</xref>
###xml 449 467 449 467 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b67-ehp0115-001646">Wilson et al. 1993</xref>
We show by gene expression analyses that low-level, physiologically relevant and proliferation-inducing doses of BPA and DHT elicit overlapping but distinct transcriptional effects in prostate cancer cells expressing the AR-T877A mutation. These data are consistent with previous reports which demonstrate that distinct AR ligands and modes of AR activation alter the specificity of the target genes modified (Davis et al. 2003; Matias et al. 2000; Wilson et al. 1993), and suggest that BPA likely uses mechanisms distinct from DHT to promote cancer cell proliferation. Although these gene-expression differences are complex, interesting and suggestive distinctions were observed. The analyses revealed that BPA exposure in cells expressing AR-T877A triggers a dramatic reduction in expression of ERbeta, a nuclear receptor suspected to negatively regulate both AR activity and prostate cancer cell proliferation. Modest reductions in ERbeta were observed after DHT treatment. Strikingly, the ability of BPA to modulate ERbeta showed cell-type specificity, as alteration in ERbeta was observed only after DHT (but not BPA) exposure in cells expressing wild-type AR or the AR-H874Y mutant. Together, these data identify ERbeta as a candidate effector of BPA action in prostate cancer cells expressing the AR-T877A mutant and demonstrate that BPA induces a unique transcriptional signature in prostate cancer cells that may be influenced by AR status.
###end p 16
###begin title 17
Materials and Methods
###end title 17
###begin title 18
Reagents
###end title 18
###begin p 19
###xml 132 134 132 134 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;2</sup>
DHT and BPA were purchased from Sigma-Aldrich Chemical Company (St. Louis, MO). Both reagents were solubilized in 100% ethanol to 10-2 M and stored at -20degreesC.
###end p 19
###begin title 20
Cell culture
###end title 20
###begin p 21
###xml 772 773 772 773 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">l</sc>
###xml 824 825 824 825 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 240 246 <span type="species:ncbi:9913">bovine</span>
LNCaP cells were obtained from American Type Culture Collection (Rockville, MD) and were used between passages 28 and 40, maintained in Iscove's modified Eagle's medium (Cellgro; Mediatech, Herndon, VA) containing 5% heat-inactivated fetal bovine serum (FBS; Biofluids, Rockville, MD). The 22Rv1 cell line was the gift of J. Jacobberger (Case Western Reserve University, Cleveland, OH) and maintained in Dulbecco's modified Eagle's medium containing 10% heat-inactivated FBS. LAPC4 cells were the gift of C. Sawyers (University of California, Los Angeles, CA) and were maintained in Iscove's modified Dulbecco's medium (Cellgro; Mediatech) containing 10% heat-inactivated FBS. Media for all cell types were supplemented with 100 U/mL penicillin-streptomycin and 2 mmole/L l-glutamine (Mediatech). Cells were grown in a 5% CO2-humidified incubator at 37degreesC. For culture in steroid-free conditions, cells were seeded in phenol red-free media containing charcoal-/dextran-treated FBS (CDT; Hyclone Laboratories, Logan, UT).
###end p 21
###begin title 22
Bromodeoxyuridine incorporation assay
###end title 22
###begin p 23
###xml 45 46 45 46 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">l</sc>
###xml 96 97 96 97 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
Cells were seeded in six-well dishes on poly-l-lysine-coated coverslips at a density of 2.5 x 105 cells per well into CDT media (allowing for depletion of AR ligands and AR activity), then supplemented with either vehicle (0.1% ethanol), 0.1 nM DHT, or 1 nM BPA the following day. After 24 hr of treatment, cells were labeled with cell proliferation-labeling reagent (Cell Proliferation Labeling reagent; Amersham, Buckinghamshire, UK) according to manufacturer's protocol, for 18 hr. Cells were then processed to detect bromodeoxyuridine (BrdU) via indirect immunofluorescence. Experiments were performed with at least six independent biological replicates, and at least 250 cells per experiment were tallied per replicate for each condition. Averages and standard deviation are shown.
###end p 23
###begin title 24
Microarray hybridization
###end title 24
###begin p 25
###xml 350 351 350 351 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 486 501 486 501 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b12-ehp0115-001646">Guo et al. 2004</xref>
###xml 503 521 503 521 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b46-ehp0115-001646">Sartor et al. 2004</xref>
###xml 528 533 <span type="species:ncbi:9606">human</span>
Vehicle control (0.1% EtOH), 0.1 nM DHT or 1 nM BPA were added to LNCaP cells 24 hr after seeding into CDT media. For each condition, three independent samples were generated for microarray analyses. After 24 hr of exposure to reagents, total RNA was isolated via TRIzol extraction for microarray analysis from each independent biological replicate (n = 3 per condition). The microarray experiments were carried out essentially as described in published reports and references therein (Guo et al. 2004; Sartor et al. 2004). The human 70-mer oligonucleotide library version 2 (22,291 optimized oligos) (QIAGEN, Alameda, CA) was suspended in 3x SSC (sodium chloride-sodium citrate) at 30 muM and printed at 22degreesC and 65% relative humidity on aminosilane-coated slides (Cel Associates, Inc. Pearland, TX) using a high-speed robotic Omnigrid machine (GeneMachines, San Carlos, CA) with Stealth SMP3 pins (Telechem, Sunnyvale, CA).
###end p 25
###begin p 26
Fluorescence-labeled cDNAs were synthesized from total RNA using an indirect amino allyl-labeling method via an oligo(dT)-primed, reverse transcriptase reaction. Imaging and data generation were carried out using a GenePix 4000A and GenePix 4000B (Axon Instruments, Union City, CA) and associated software from Axon Instruments (Foster City, CA). The microarray slides were scanned with dual lasers with wavelength frequencies to excite cyanine (Cy) 3 and Cy5 fluorescence emittance. Images were captured in JPEG and TIFF files, and DNA spots captured by the adaptive circle segmentation method. Information extraction for a given spot is based on the median value for the signal pixels minus the median value for the background pixels to produce a gene set data file for all the DNA spots. The Cy3 and Cy5 fluorescence signal intensities were normalized.
###end p 26
###begin title 27
Statistical analysis and functional testing of microarrays
###end title 27
###begin p 28
###xml 263 278 263 278 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b12-ehp0115-001646">Guo et al. 2004</xref>
###xml 280 298 280 298 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b46-ehp0115-001646">Sartor et al. 2004</xref>
###xml 382 383 382 383 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">M</italic>
###xml 399 400 399 400 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</italic>
###xml 447 448 447 448 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">M</italic>
###xml 454 455 454 455 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 465 466 465 466 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 475 476 475 476 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</italic>
###xml 483 484 483 484 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 494 495 494 495 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 662 663 662 663 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">M</italic>
###xml 681 682 681 682 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</italic>
###xml 792 793 792 793 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</italic>
###xml 861 862 861 862 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</italic>
###xml 1009 1034 1009 1034 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b10-ehp0115-001646">Dudiot and Fridlyand 2002</xref>
###xml 1047 1048 1047 1048 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
###xml 1141 1151 1141 1151 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b51-ehp0115-001646">Smyth 2004</xref>
###xml 1321 1322 1321 1322 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
The data representing background subtracted spot intensities generated by GenePix Pro software ,version 5.0 (Axon Instruments) were analyzed to identify differentially expressed genes. Data normalization was performed in two steps for each microarray separately (Guo et al. 2004; Sartor et al. 2004). First, background adjusted intensities were log-transformed and the differences (M) and averages (A) of log-transformed values were calculated as M = log2(x1) - log2(x2) and A = [log2(x1) + log2(x2)]/2, where x1 and x2 denote the Cy5 and Cy3 intensities, respectively. Second, normalization was performed by fitting the array-specific local regression model of M as a function of A. Normalized log-intensities for the two channels were then calculated by adding half the normalized ratio to A for the Cy5 channel and subtracting half the normalized ratio from A for the Cy3 channel. The statistical analysis was performed for each gene separately by fitting the following analysis of variance (ANOVA) model (Dudiot and Fridlyand 2002). Resulting t-statistics from each contrast were modified using an empirical Bayesian moderated-T method (Smyth 2004). This method uses variance estimates from all genes to improve the variance estimates of each individual gene. Estimates of fold change were calculated, and genes with p-value < 0.05, fold change > 2, and average spot intensity > 100 were considered for follow-up. Data analysis was performed using the statistical software R () and the Bioconductor platform (). Average linkage hierarchial clustering was performed using the uncentered correlation similarity metric for the genes considered for follow-up.
###end p 28
###begin p 29
###xml 131 149 131 149 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b17-ehp0115-001646">Hosack et al. 2003</xref>
###xml 367 385 367 385 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b17-ehp0115-001646">Hosack et al. 2003</xref>
The gene list was analyzed to determine which gene categories were enriched with differentially expressed genes using EASE/ DAVID (Hosack et al. 2003), and the gene sets tested were the three branches of the Gene Ontology (GO) database (). Fisher's exact probability, using the FDR (false discovery rate) multiple testing adjustment, was calculated for each GO term (Hosack et al. 2003).
###end p 29
###begin title 30
Reverse transcriptase polymerase chain reaction (PCR)
###end title 30
###begin p 31
###xml 230 233 229 232 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PSA</italic>
###xml 266 269 265 268 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PSA</italic>
###xml 304 309 303 308 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GAPDH</italic>
###xml 346 351 345 350 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GAPDH</italic>
###xml 388 390 387 389 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ER</italic>
###xml 429 431 425 427 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ER</italic>
###xml 471 476 464 469 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">WISP3</italic>
###xml 509 514 502 507 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">WISP3</italic>
###xml 544 549 537 542 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FKBP5</italic>
###xml 582 587 575 580 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FKBP5</italic>
###xml 713 718 706 711 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GAPDH</italic>
###xml 780 782 755 757 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ER</italic>
###xml 846 851 800 805 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">WISP3</italic>
###xml 913 918 849 854 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FKBP5</italic>
RNA was isolated from cells by TRIzol extraction, of which 5 mug was used to generate cDNA with random hexamers using the ThermoScript RT-PCR system (Invitrogen, Carlsbad, CA). PCRs were performed using the following primer sets: PSA forward: CTTGTAGCCTCTCGTG GCAC; PSA reverse: GACCTTCATAG CATCCGT GAG; GAPDH forward: CCACCCCATG GCAAATTCCATGCA; GAPDH reverse: TCTAGACGGCAGGTC AGGTCCACC; ERbeta forward: CAGCAT TCCCAGCAAT GTCAC; ERbeta reverse: GGTAAGGT GTTCTAGCGATCTTG; WISP3 forward: AAGCAGGCTCTGG GCAGCTA; WISP3 reverse: GACGTTGT TGCAGTTCC; FKBP5 forward: GAGAAA AGCCAGCATAAAGC; FKBP5 reverse: TCTAGAACTTGCGTGGAAAG. Amplifications were performed using Taq DNA polymerase with the following conditions: PSA and GAPDH 94degreesC 30 sec, 54degreesC 30 sec, and 72degreesC 30 sec; ERbeta 94degreesC 30 sec, 56degreesC 1 min, and 73degreesC 1 min; WISP3 95degreesC 30 sec, 60degreesC 30 sec, and 68degreesC 30 sec; FKBP5 95degreesC 30 sec, 56degreesC 1 min, and 73degreesC 1 min. Resulting products were resolved by agarose gel electrophoresis.
###end p 31
###begin title 32
Real-time PCR analysis of ERbeta
###end title 32
###begin p 33
###xml 924 941 888 905 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b33-ehp0115-001646">Leung et al. 2006</xref>
###xml 1096 1102 1060 1066 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">hGAPDH</italic>
###xml 1135 1152 1099 1116 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b33-ehp0115-001646">Leung et al. 2006</xref>
###xml 1262 1263 1226 1227 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 1274 1275 1238 1239 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
Five micrograms of total RNA were reverse-transcribed into cDNA by Superscript III reverse transcriptase (Invitrogen) according to the manufacturer's instructions. Real-time PCR reactions containing Power SYBR Green PCR Master Mix (Applied Biosystems), 250 ng cDNA template and 500 nM of ERbeta specific primers (ERbeta forward: 5'-TGG CTA ACC TCC TGA TGC TC-3'; ERbeta reverse: 5'-TCC AGC AGC AGG TCA TAC AC-3') were prepared. Real-time PCR reactions in an Applied Biosystems Prism 7900HT (Applied Biosystems) were initiated by heating to 50degreesC for 2 min and then to 95degreesC for 10 min. They were followed by 40 cycles of denaturation (95degreesC for 15 sec) and annealing/extension (63degreesC for 30 sec). Dissociation curves of each reaction were collected to evaluate the quality of the end products. A standard curve for ERbeta was constructed by serial dilutions of the expression vector prepared previously (Leung et al. 2006). The copy number was determined according to the published formula provided in the Applied Biosystems manual (). Loading control was normalized by using hGAPDH level using a published method (Leung et al. 2006). Statistically analysis was performed using one-way ANOVA with Newman-Keuls test for multiple comparisons: *p < 0.05, **p < 0.01.
###end p 33
###begin title 34
Immunoblotting
###end title 34
###begin p 35
###xml 723 727 <span type="species:ncbi:9925">Goat</span>
###xml 733 739 <span type="species:ncbi:9986">rabbit</span>
Cells were treated as described for RNA isolation. However, for protein analyses, total cells were pelleted and whole cell lysates prepared using r adioimmunoprecipitation buffer supplemented with standard protease inhibitors and phenyl-methylsulfonyl fluoride. Lysates were subjected to brief sonication and clarified by centrifugation. Equal protein concentrations (approximately 20 mug) were loaded and subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Proteins were transferred to Immobilon membrane (Millipore Corp., Bedford, MA) and immunoblotted for ERbeta or CDK4 (cyclin dependent kinase 4, loading control) (antisera: H-150 and H-22, respectively; Santa Cruz Biotechnology, Santa Cruz, CA). Goat-anti rabbit (Alexa Fluor 680 A21076 1:10,000; Molecular Probes, Eugene, OR) was used to visualize the antibody-antigen complex.
###end p 35
###begin title 36
Results
###end title 36
###begin title 37
BPA initiates androgen-independent prostate cancer cell proliferation in cells harboring the AR-T877A mutation
###end title 37
###begin p 38
###xml 162 171 162 171 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f1-ehp0115-001646">Figure 1A</xref>
###xml 504 505 504 505 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 745 754 745 754 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f1-ehp0115-001646">Figure 1B</xref>
###xml 836 857 836 857 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b66-ehp0115-001646">Wetherill et al. 2002</xref>
###xml 859 863 859 863 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b64-ehp0115-001646">2005</xref>
###xml 1371 1392 1359 1380 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b66-ehp0115-001646">Wetherill et al. 2002</xref>
###xml 1394 1398 1382 1386 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b64-ehp0115-001646">2005</xref>
###xml 1400 1404 1388 1392 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b65-ehp0115-001646">2006</xref>
To dissect the mechanisms by which BPA modulated mutant AR activity, conditions were used wherein BPA exposure resulted in a significant proliferative advantage (Figure 1A). Briefly, AR-T877A-expressing prostate cancer cells (LNCaP) were initially cultured in hormone-depleted conditions (CDT), to suppress cell cycle progression and deplete endogenous AR of ligand. After 24 hr, cells were treated with DHT, BPA, or vehicle (0.1% ethanol; EtOH) and pulsed with 5-bromo-2-deoxyuridine (BrdU) to measure G1-S phase progression. As expected, androgen depletion significantly attenuated cell cycle progression compared with cells cultured in the presence of physiological levels of DHT (0.1 nM) (approximate 3-fold reduction in BrdU incorporation, Figure 1B). Consistent with previous reports for cells carrying BPA-responsive AR mutants (Wetherill et al. 2002, 2005), BPA exposure also induced significant S-phase progression compared with vehicle control (approximately 2.5-fold induction over vehicle control). Similar trends were observed after increasing time periods postligand stimulation or when AR ligand stimulation was applied after prolonged periods of hormone ablation (data not shown). Previous studies showed that BPA administration results in dose-dependent proliferation (with concomitant increase in cell number) of LNCaP cells in the absence of androgen (Wetherill et al. 2002, 2005, 2006). Therefore, in this experimental paradigm, DHT and BPA each elicit significant effects on cellular proliferation, and these strategies can be used to dissect the molecular impact of BPA on prostate cancer.
###end p 38
###begin title 39
BPA elicits a distinct transcriptome in prostate cancer cells
###end title 39
###begin p 40
###xml 199 207 199 207 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f1-ehp0115-001646">Figure 1</xref>
###xml 645 666 645 666 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b66-ehp0115-001646">Wetherill et al. 2002</xref>
###xml 1132 1141 1132 1141 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f2-ehp0115-001646">Figure 2A</xref>
###xml 1557 1561 1557 1561 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KLK3</italic>
###xml 1590 1593 1590 1593 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PSA</italic>
###xml 1859 1860 1859 1860 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 2254 2263 2254 2263 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f2-ehp0115-001646">Figure 2B</xref>
To determine the specific effects of BPA that underlie its pro-proliferative capacity, parallel cultures were examined for alterations in gene expression. Briefly, cells were treated as described in Figure 1 with either vehicle (EtOH), DHT, or BPA before RNA isolation. A time course was initially performed, where it was determined that BPA-induced PSA expression peaks at 24 hr poststimulation compared with approximately 16 hr after DHT stimulation (data not shown). The delay in peak observation is consistent with previous observations that AR nuclear translocation facilitated by BPA is delayed compared with DHT-induced AR translocation (Wetherill et al. 2002). Therefore, this time point was chosen for subsequent microarray analyses. RNA for each condition (EtOH, DHT, and BPA) was isolated from three independent experimental cultures to determine the change in transcript levels for each condition and when evaluated in triplicate, genes passing the ANOVA criteria were further analyzed to create a cluster heat map. A heat map was generated using the fold change estimates and averaged across samples. As can be seen in Figure 2A, BPA (column 1) and DHT (column 2) showed some similar gene expression profiles with comparable patterns of gene down-regulation (green) and up-regulation (red) relative to the vehicle control. However, column 3 provides a visual mechanism to compare the profile of BPA with that of DHT and exemplifies the differences in the genetic profile induced by the two ligands. An important control and point of reference, KLK3 (prostate-specific antigen, PSA, UniGene ID# Hs.171995) was up-regulated by both BPA and DHT but was more robustly activated by DHT, as can be seen by the green band in lane 3. Statistical analyses revealed that a total of 283 genes showed significant alteration relative to vehicle control (with p < 0.05, > 2-fold change in gene expression and average intensity > 100 as criteria for significant changes). Of these, only 51 genes were common to both BPA and DHT (38 up-regulated and 13 down-regulated). However, 88 genes were uniquely regulated by BPA treatment (51 up-regulated and 37 down-regulated), and 144 genes were exclusive to DHT treatment (94 up-regulated and 50 down-regulated) (Figure 2B). These data suggest that although the proliferative response to DHT or BPA is congruent, the gene profiles after exposure are divergent between the canonical ligand DHT and the environmental contaminant BPA.
###end p 40
###begin p 41
###xml 281 290 281 290 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f2-ehp0115-001646">Figure 2C</xref>
###xml 755 759 755 759 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KLK3</italic>
###xml 771 776 771 776 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FKBP5</italic>
###xml 922 927 922 927 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FKBP5</italic>
###xml 1071 1088 1071 1088 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b34-ehp0115-001646">Magee et al. 2006</xref>
###xml 1229 1233 1229 1233 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FIGF</italic>
###xml 1380 1399 1380 1399 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b23-ehp0115-001646">Kaushal et al. 2005</xref>
###xml 1406 1411 1406 1411 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">WISP3</italic>
###xml 1675 1680 1675 1680 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">WISP3</italic>
###xml 1799 1816 1799 1816 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b25-ehp0115-001646">Kleer et al. 2004</xref>
###xml 1868 1874 1868 1874 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SPBPBP</italic>
###xml 1964 1969 1964 1969 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CRBP1</italic>
###xml 2231 2251 2231 2251 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b21-ehp0115-001646">Jeronimo et al. 2004</xref>
###xml 2253 2271 2253 2271 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b54-ehp0115-001646">Suzuki et al. 2006</xref>
###xml 2279 2283 2279 2283 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGF1</italic>
###xml 2439 2456 2439 2456 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b6-ehp0115-001646">Craft et al. 1999</xref>
###xml 2458 2475 2458 2475 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b7-ehp0115-001646">Culig et al. 1994</xref>
###xml 2545 2547 2545 2547 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ER</italic>
###xml 2675 2694 2672 2691 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b19-ehp0115-001646">Imamov et al. 2004a</xref>
###xml 2696 2701 2693 2698 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b20-ehp0115-001646">2004b</xref>
###xml 2703 2721 2700 2718 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b61-ehp0115-001646">Weihua et al. 2002</xref>
###xml 2253 2259 <span type="species:ncbi:8164">Suzuki</span>
Key target genes critical for DHT-mediated AR-dependent proliferation are largely unknown. Therefore, the expression changes induced by mitogenic BPA or DHT were also analyzed via GO to determine cellular pathways that may be altered by AR activation with these disparate ligands (Figure 2C). The GO terms that were affected are of significant interest to prostate development and organ homeostasis and function, as well as prostatic disease, and include genes involved in the regulation of cell proliferation, differentiation, organogenesis, and growth factor pathways. Among these categories, several previously described direct or suspected AR gene targets were identified in both the DHT- and BPA-treated cohorts, including prostate specific antigen (KLK3/ PSA), and FKBP5 (FK506 binding protein 5; UniGene ID Hs.7557), a member of the immunophilin protein family involved in protein trafficking and folding. Notably, FKBP5 has been shown to be up-regulated in xenograft models of androgen-independent prostate cancer and induced by androgen exposure in LNCaP cells (Magee et al. 2006). In addition, several potentially key effectors of prostate cancer cell proliferation were identified in the BPA-treated cohort, including FIGF (c-fos-induced growth factor, also called VEGF-D; UniGene ID Hs.11392), which has been associated with advanced-stage metastatic prostate cancer (Kaushal et al. 2005). The WISP3 (WNT-1 inducible signaling pathway protein 3, UniGene ID Hs.194678) gene, whose protein product is a member of the CCN (connective tissue growth factor, cysteine-rich protein 61, and nephroblastoma overexpressed gene) family, was also among those induced by BPA. WISP3 is thought to have important roles in carcinogenesis and has identified functions in cell growth and differentiation (Kleer et al. 2004). Other potential effectors of BPA action included SPBPBP (DNA-binding protein amplifying expression of surfactant protein B; UniGene ID Hs.3134), CRBP1, [cellular retinol-binding protein type 1; UniGene ID Hs.208597, a member of the retinoids, known to be involved in cell growth, differentiation, and carcinogenesis, and which specifically has been found to have altered methylation patterns in prostate cancer (Jeronimo et al. 2004; Suzuki et al. 2006)], and IGF1 [insulin-like growth factor (UniGene ID Hs.160562), thought to induce cell survival/proliferation and a known activator of ligand-independent AR activity (Craft et al. 1999; Culig et al. 1994)]. Last, the most significantly altered gene in the BPA data set was ERbeta (UniGene ID# Hs.443150), which has been proposed to antagonize AR activity and limit proliferation in prostatic epithelia (Imamov et al. 2004a, 2004b; Weihua et al. 2002).
###end p 41
###begin p 42
###xml 511 520 511 520 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f3-ehp0115-001646">Figure 3A</xref>
###xml 641 650 641 650 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f3-ehp0115-001646">Figure 3A</xref>
###xml 795 804 795 804 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f3-ehp0115-001646">Figure 3A</xref>
###xml 1032 1041 1029 1038 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f2-ehp0115-001646">Figure 2C</xref>
###xml 1197 1206 1191 1200 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f3-ehp0115-001646">Figure 3A</xref>
Given the potential importance of these factors in facilitating BPA-induced cellular proliferation, several of the pro-proliferative genes and/or AR target genes were analyzed for alteration in response to BPA treatment. Using conditions identical to those used for the microarray studies, cells were placed in an environment of androgen ablation and subsequently stimulated with DHT or BPA for 24 hr. Initially, the AR target gene PSA was analyzed. As expected, both DHT and BPA increased PSA mRNA expression (Figure 3A, left panel). Conversely, FKBP5 was increased by DHT (8-fold over EtOH) but not significantly induced by BPA treatment (Figure 3A, right panel). By contrast, BPA treatment increased WISP3 (2-fold over EtOH control), whereas DHT had no significant effect on gene expression (Figure 3A, right panel). Last, analyses of ERbeta transcript levels were explored by reverse transcriptase PCR, as reduction of this mRNA was initiated by both DHT and BPA (compare -2.6 fold change by DHT with -4.8-fold change by BPA in Figure 2C). Interestingly, both microarray and reverse transcriptase PCR validation showed that BPA facilitated more significant down-regulation of ERbeta than DHT (Figure 3A, right panel, lane 3; 0.46-fold expression compared with EtOH for BPA).
###end p 42
###begin p 43
###xml 170 179 167 176 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f3-ehp0115-001646">Figure 3B</xref>
###xml 402 403 393 394 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 524 525 500 501 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 534 543 510 519 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f3-ehp0115-001646">Figure 3B</xref>
###xml 647 648 620 621 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 883 892 850 859 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f3-ehp0115-001646">Figure 3C</xref>
Real-time PCR was used to accurately quantify the level of ERbeta transcript down-regulation induced by DHT and BPA treatment of LNCaP prostate cancer cells. As shown in Figure 3B, cells cultured under conditions of androgen ablation (EtOH vehicle treatment) demonstrated approximately 20 relative copy numbers of ERbeta transcript. DHT treatment reduced ERbeta transcript to < 10 (a reduction of 50%, p < 0.05). Remarkably, BPA exposure dramatically decreased ERbeta transcript copy number (approximately 4, 80% reduction, p < 0.01; Figure 3B). There was not a strong statistical difference between the DHT- and BPA-mediated reduction in ERbeta (p > 0.05). These results were further validated at the protein level in parallel assays by immunoblotting for ERbeta. Therein, exposure of the cells to mitogenic doses of BPA and DHT resulted in a detectable decrease in ERbeta protein (Figure 3C, compare lanes 1, 3). CDK4 was used as the loading control. Collectively, these data indicate that although both BPA and DHT can activate mutant AR and resultant cellular proliferation in prostate cancer cells, each agent induces a unique molecular signature, wherein genetic profiles induced by mitogenic doses of DHT or BPA showed both overlapping (e.g., PSA and ERbeta) and divergent (e.g., FKBP5, WISP3) responses.
###end p 43
###begin title 44
BPA-mediated regulation of ERbeta is cell-type specific
###end title 44
###begin p 45
###xml 174 191 171 188 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b1-ehp0115-001646">Adams et al. 2002</xref>
###xml 193 209 190 206 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b31-ehp0115-001646">Leav et al. 2001</xref>
###xml 983 984 968 969 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 1108 1117 1090 1099 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f4-ehp0115-001646">Figure 4A</xref>
The observation that BPA significantly reduced ERbeta expression was striking, as this receptor plays significant roles in both prostate development and disease progression (Adams et al. 2002; Leav et al. 2001). Therefore, the specificity of BPA-induced ERbeta down-regulation was determined. The effect of BPA treatment on ERbeta transcript levels was examined in two additional prostate cancer cell lines, 22Rv1 and LAPC4. 22Rv1 cells are androgen-independent prostate cancer cells that express the AR-H874Y mutant. 22Rv1 cells were treated under identical conditions as previously described, cells were switched to steroid deprived media for 24 hr, then treatments (EtOH vehicle control, DHT or BPA) were added for 24 hr. As shown, cells treated under conditions of hormone ablation demonstrated a relative copy number of 7 (ERbeta over GAPDH control), as determined by quantitative reverse transcriptase PCR. DHT reduced the level of ERbeta transcript copy by approximately 50% (p < 0.05); however, contrary to observations in LNCaP cells, exposure to BPA had no effect on ERbeta transcript copy number (Figure 4A).
###end p 45
###begin p 46
###xml 328 329 319 320 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 444 453 432 441 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="f4-ehp0115-001646">Figure 4B</xref>
The impact of BPA exposure on ERbeta transcript was examined further in the LAPC4 prostate cancer cell line, which harbors wild-type AR and is androgen dependent. Strikingly, although the relative level of ERbeta was lower in LAPC4 cells, DHT treatment still resulted in approximately a 40% reduction in ERbeta gene transcript (p < 0.05). However, similar to the effect seen in 22Rv1 cells, BPA exposure did not alter ERbeta transcript levels (Figure 4B), as evidenced by further reverse transcriptase PCR (right panel) and quantified by quantitative PCR (left panel). Combined, these data demonstrate that the effect of BPA on reduction of ERbeta gene expression is cell specific and correlated with cells expressing the BPA-responsive AR-T877A mutant.
###end p 46
###begin title 47
Discussion
###end title 47
###begin p 48
###xml 139 163 139 163 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b11-ehp0115-001646">Feldman and Feldman 2001</xref>
###xml 165 184 165 184 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b15-ehp0115-001646">Hirawat et al. 2003</xref>
###xml 186 206 186 206 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b36-ehp0115-001646">Marcelli et al. 2000</xref>
###xml 208 227 208 227 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b40-ehp0115-001646">Navarro et al. 2002</xref>
###xml 229 247 229 247 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b55-ehp0115-001646">Taplin et al. 2003</xref>
###xml 249 273 249 273 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b57-ehp0115-001646">Veldscholte et al. 1992a</xref>
###xml 612 633 612 633 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b65-ehp0115-001646">Wetherill et al. 2006</xref>
###xml 1416 1432 1413 1429 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b31-ehp0115-001646">Leav et al. 2001</xref>
###xml 1434 1456 1431 1453 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b44-ehp0115-001646">Pravettoni et al. 2007</xref>
###xml 1458 1476 1455 1473 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b60-ehp0115-001646">Weihua et al. 2001</xref>
###xml 102 110 <span type="species:ncbi:9606">patients</span>
Somatic mutation of the AR is known to drive recurrent tumor formation in a significant percentage of patients undergoing hormone therapy (Feldman and Feldman 2001; Hirawat et al. 2003; Marcelli et al. 2000; Navarro et al. 2002; Taplin et al. 2003; Veldscholte et al. 1992a), and it has been shown previously that selected AR mutants become receptive to activation by the environmental contaminant BPA. The clinical ramifications of BPA activating tumor-derived mutant ARs and inducing androgen-independent tumor cell proliferation may be substantial, as BPA can reduce therapeutic efficacy in xenograft models (Wetherill et al. 2006). While these data point toward the potential for BPA to assist tumor cells in escaping therapy, the molecular mechanisms of this process were not well understood. In this study, the molecular consequence of BPA action was identified under conditions in which BPA promotes androgen-independent proliferation. Gene expression analyses revealed that in AR-T877A-expressing cells, BPA elicited an overlapping but distinct molecular signature compared with that induced by exposure to canonical AR ligand (DHT). Unexpectedly, detailed examination of the most significant targets demonstrated that BPA exposure elicited dramatic reduction in expression of ERbeta, a nuclear receptor that is proposed to antagonize AR activity and androgen-dependent proliferation in prostatic epithelia (Leav et al. 2001; Pravettoni et al. 2007; Weihua et al. 2001). Comparative analyses revealed that while DHT exposure also reduced ERbeta, this effect was marginal compared with the BPA response. Last, the ability of BPA (but not DHT) to attenuate ERbeta function appears to be specific to cell type and putatively receptor specific, as BPA had no detectable effect on ERbeta expression in cells containing wild-type AR or AR-H874Y. Notably, these also represent cell types in which BPA fails to induce cellular proliferation. Together, these data indicate that the ability of BPA to induce androgen-independent cellular proliferation is associated with AR-T877A expression and a unique gene expression signature that involves down-regulation of ERbeta.
###end p 48
###begin p 49
###xml 334 352 334 352 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b49-ehp0115-001646">Shioda et al. 2006</xref>
###xml 548 571 545 568 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b5-ehp0115-001646">Cappelletti et al. 2003</xref>
###xml 824 845 821 842 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b50-ehp0115-001646">Singleton et al. 2006</xref>
Combined with these observations, the concept that BPA induces cell-specific transcriptional profiles is emerging. For example, transcriptional analysis of BPA exposure on breast cancer cells (MCF-7) revealed that BPA up-regulated a significant number of genes involved in cell cycle progression and purine and pyrimidine metabolism (Shioda et al. 2006), reaffirming the proliferative biological action of this compound in estrogen-dependent tissues. Interestingly, it has been shown that BPA exposure increases ERbeta in some breast cancer lines (Cappelletti et al. 2003), suggesting that the direct activation of ERs by BPA may facilitate the proliferative response to these tissues. Additionally, it has been shown that higher levels of BPA uniquely regulate growth- and development-related genes in breast cancer cells (Singleton et al. 2006). From these data it is clear that in estrogen-sensitive mammary tissues, BPA exposure modulates pathways with important biological outcomes (e.g., cell cycle progression), and that the effects of BPA augment the known proliferative response to ER activation in this tissue type.
###end p 49
###begin p 50
###xml 426 441 411 426 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b30-ehp0115-001646">Lau et al. 2000</xref>
###xml 443 459 428 444 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b31-ehp0115-001646">Leav et al. 2001</xref>
###xml 461 476 446 461 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b35-ehp0115-001646">Mak et al. 2006</xref>
###xml 478 500 463 485 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b44-ehp0115-001646">Pravettoni et al. 2007</xref>
###xml 619 638 601 620 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b16-ehp0115-001646">Horvath et al. 2001</xref>
###xml 640 661 622 643 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b38-ehp0115-001646">McPherson et al. 2007</xref>
###xml 663 683 645 665 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b43-ehp0115-001646">Pasquali et al. 2001</xref>
###xml 710 729 692 711 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b19-ehp0115-001646">Imamov et al. 2004a</xref>
###xml 835 857 814 836 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b39-ehp0115-001646">Migliaccio et al. 2000</xref>
###xml 1056 1075 1032 1051 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b16-ehp0115-001646">Horvath et al. 2001</xref>
###xml 1077 1091 1053 1067 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b22-ehp0115-001646">Ji et al. 2005</xref>
###xml 1093 1108 1069 1084 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b29-ehp0115-001646">Lai et al. 2004</xref>
###xml 1110 1126 1086 1102 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b31-ehp0115-001646">Leav et al. 2001</xref>
###xml 1239 1258 1212 1231 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b19-ehp0115-001646">Imamov et al. 2004a</xref>
###xml 1260 1265 1233 1238 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b20-ehp0115-001646">2004b</xref>
###xml 1290 1308 1263 1281 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b60-ehp0115-001646">Weihua et al. 2001</xref>
###xml 1555 1573 1525 1543 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b28-ehp0115-001646">Kuiper et al. 1998</xref>
###xml 1575 1592 1545 1562 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b33-ehp0115-001646">Leung et al. 2006</xref>
###xml 1709 1728 1676 1695 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b16-ehp0115-001646">Horvath et al. 2001</xref>
###xml 1730 1746 1697 1713 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b31-ehp0115-001646">Leav et al. 2001</xref>
###xml 1748 1766 1715 1733 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b60-ehp0115-001646">Weihua et al. 2001</xref>
###xml 1867 1882 1831 1846 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b24-ehp0115-001646">Kim et al. 2002</xref>
###xml 1884 1899 1848 1863 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b30-ehp0115-001646">Lau et al. 2000</xref>
###xml 1901 1921 1865 1885 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b41-ehp0115-001646">Neubauer et al. 2003</xref>
###xml 2475 2496 2428 2449 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b9-ehp0115-001646">Dehm and Tindall 2006</xref>
###xml 2808 2826 2755 2773 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b2-ehp0115-001646">Arnold et al. 2005</xref>
###xml 2828 2846 2775 2793 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b47-ehp0115-001646">Segawa et al. 2002</xref>
###xml 1133 1138 <span type="species:ncbi:10090">mouse</span>
###xml 1337 1342 <span type="species:ncbi:9606">human</span>
The ability of BPA to induce ERbeta expression is in marked contrast to the observations herein, where BPA significantly reduced ERbeta mRNA and protein accumulation. Although the biological functions of ERbeta remain poorly understood, in contrast to the proliferative role of ERbeta in mammary tissue, it is hypothesized that functions of ERbeta in the prostate include antiproliferative action and regulation of apoptosis (Lau et al. 2000; Leav et al. 2001; Mak et al. 2006; Pravettoni et al. 2007). Studies have demonstrated that loss of ERbeta signaling in prostatic epithelium results in increased proliferation (Horvath et al. 2001; McPherson et al. 2007; Pasquali et al. 2001) and up-regulation of AR (Imamov et al. 2004a). Molecular analyses have shown that ERbeta can form a direct complex with AR and abrogate its activity (Migliaccio et al. 2000). Moreover, direct analysis of prostate disease progression has shown that ERbeta expression declines as prostate cancer develops [although expression is regained in lymph node and bone metastasis (Horvath et al. 2001; Ji et al. 2005; Lai et al. 2004; Leav et al. 2001)]. In mouse model systems, prostatic epithelial hyperplasia can be attenuated by specific activation of ERbeta (Imamov et al. 2004a, 2004b; McPherson et al. 2002; Weihua et al. 2001 Weihua et al. 2007). In the human population, the chemo-prevention and protective nature of phytoestrogens in prostate cancer is hypothesized to rely on the high binding affinity and activating potential of these estrogenic compounds for ERbeta (Kuiper et al. 1998; Leung et al. 2006). Collectively, these data indicate that ERbeta plays a significant role in regulating normal prostate homeostasis (Horvath et al. 2001; Leav et al. 2001; Weihua et al. 2001), and that loss of ERbeta plays a possible role in enhancing the survival of prostate cancer cells (Kim et al. 2002; Lau et al. 2000; Neubauer et al. 2003). The present observation that BPA initiates ERbeta down-regulation suggests that this may be one mechanism by which BPA bolsters overall AR activity, thereby promoting a proliferative response. The observation that DHT modestly altered ERbeta levels was not expected, as ERbeta has not been well documented as a target (direct or indirect) of androgen action. Of note, however, is that a significant fraction of published microarray studies using the AR-dependent prostate cancer cell lines have been performed using high doses of androgen (>/=10 nM) (Dehm and Tindall 2006), which induce profound cell cycle arrest in prostate cancer cells. Thus, it is possible that effects on ERbeta may be masked by such experimental conditions. Furthermore, scrutiny of the literature demonstrated that down-regulation of ERbeta by DHT has been previously observed but had not yet been validated (Arnold et al. 2005; Segawa et al. 2002). While the complete molecular complexities of mitogenic signaling in prostate cancer cells remain to be elucidated, it would be interesting to continue this line of experimentation with an analysis of gene regulation as a function of time with the various mitogenic ligands. However, together these collective observations put forward the intriguing hypothesis that the proliferative effects of BPA may be at least partially due to the manipulation of ERbeta levels.
###end p 50
###begin p 51
###xml 261 282 258 279 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b64-ehp0115-001646">Wetherill et al. 2005</xref>
###xml 682 703 673 694 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b64-ehp0115-001646">Wetherill et al. 2005</xref>
###xml 881 902 872 893 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b64-ehp0115-001646">Wetherill et al. 2005</xref>
###xml 1782 1802 1755 1775 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b52-ehp0115-001646">Susiarjo et al. 2007</xref>
###xml 2182 2197 2143 2158 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b70-ehp0115-001646">Zhu et al. 2004</xref>
###xml 2218 2221 2179 2182 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cis</italic>
###xml 2399 2421 2354 2376 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b68-ehp0115-001646">Zhang et al., in press</xref>
The ability of BPA to govern ERbeta levels was observed only in cells expressing the AR-T877A mutant. This observation shows critical specificity in BPA action; cells expressing wild-type AR or AR-T874Y, which are nonresponsive to the mitogenic effects of BPA (Wetherill et al. 2005), were impervious to the BPA-facilitated changes in ERbeta. Although presently the possibility that cell-type specificity is controlled by factors in addition to AR mutation, it is intriguing to speculate about the role of mutant AR in facilitating BPA-mediated ERbeta regulation. Previous work has shown that BPA can activate AR-H874Y and elicit transactivation of target genes in reporter assays (Wetherill et al. 2005); however, because of the ligand-independent nature of this cell line, AR activation by either DHT or BPA does not facilitate proliferation in AR-H874Y-dependent (22Rv1) cells (Wetherill et al. 2005). With regard to wild-type AR, BPA is not known to bind to or activate this receptor at the doses used, and LAPC4 cells (which express wild-type AR) are not responsive to androgen-independent cellular proliferation by BPA exposure. By comparison, DHT-mediated reduction of ERbeta expression was relatively equivalent in each of these lines, thus indicating that the capacity to modulate ERbeta remains intact. Hence, the ability of BPA to alter ERbeta levels appears to correlate to the mitogenic capacity of BPA. Future studies will be directed at dissecting the mechanism by which AR ligands alternately regulate ERbeta and the contribution of differential mutations of AR to this process. In addition, given that BPA can bind to ERbeta directly, it will also be important to determine whether the impact of BPA on ERbeta is direct or indirect. Recent work by Susiarjo et al. (Susiarjo et al. 2007) have demonstrated that the adverse effects of BPA on oocyte development requires ERbeta further supporting the notion that the salient mode of action for BPA may be through alterations in ERbeta function. Remarkably, it still remains largely unknown what controls ERbeta expression in the prostate. Although epigenetic regulation of ERbeta in prostate cancer has been reported (Zhu et al. 2004), knowledge of what cis-acting factors directly interact with the ERbeta promoter is very limited; AP-2 was recently found to be a promising transcription factor that regulates ERbeta gene expression (Zhang et al., in press).
###end p 51
###begin p 52
In summary, the present study demonstrates that BPA uses a cell-specific gene expression signature in prostate cancer cells expressing a somatic mutation of AR, and that a major molecular consequence of BPA action is down-regulation of ERbeta These studies provide insight into a potentially novel mechanism by which BPA can promote AR-T877A activity and androgen-independent cellular proliferation. Given the critical importance of controlling AR activity for prostate cancer therapy, the present study provides the foundation for future investigations directed at dissecting the role of BPA and ERbeta in controlling prostate cancer growth and/or progression.
###end p 52
###begin p 53
We thank S. Khan, E. Knudsen, A. Puga, and all members of both Knudsen laboratories for critical ongoing discussions and insight.
###end p 53
###begin p 54
This work was supported by National Institutes of Health grants ES93404 and CA099996 (to K.E.K.), National Institute of Environmental Health Sciences (NIEHS) Center for Environmental Genetics core grant E30-ES-06096 and NIEHS Environmental Mutagenesis and Cancer training grant ES-07250-16 (J.K.H-W).
###end p 54
###begin title 55
References
###end title 55
###begin article-title 56
###xml 78 83 <span type="species:ncbi:9606">human</span>
Expression of estrogen receptor beta in the fetal, neonatal, and pre-pubertal human prostate
###end article-title 56
###begin article-title 57
###xml 121 126 <span type="species:ncbi:9606">human</span>
Comparative effects of DHEA vs. testosterone, dihydrotestosterone, and estradiol on proliferation and gene expression in human LNCaP prostate cancer cells
###end article-title 57
###begin article-title 58
###xml 79 84 <span type="species:ncbi:9606">human</span>
Structure-function relationship of estrogen receptor alpha and beta: impact on human health
###end article-title 58
###begin article-title 59
###xml 61 66 <span type="species:ncbi:9606">human</span>
Urinary concentrations of bisphenol A and 4-nonylphenol in a human reference population
###end article-title 59
###begin article-title 60
###xml 66 71 <span type="species:ncbi:9606">human</span>
Selective modulation of ER-beta by estradiol and xenoestrogens in human breast cancer cell lines
###end article-title 60
###begin article-title 61
A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neutyrosine kinase
###end article-title 61
###begin article-title 62
Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor
###end article-title 62
###begin article-title 63
Functional androgen receptor confers sensitization of androgen-independent prostate cancer cells to anti-cancer therapy via caspase activation
###end article-title 63
###begin article-title 64
Molecular regulation of androgen action in prostate cancer
###end article-title 64
###begin article-title 65
A prediction-based resampling method for estimating the number of clusters in a dataset
###end article-title 65
###begin article-title 66
The development of androgen-independent prostate cancer
###end article-title 66
###begin article-title 67
###xml 10 15 <span type="species:ncbi:9606">human</span>
Effect of human chorionic ganadotropin in the gene-expression profile of MCF-7 cells
###end article-title 67
###begin article-title 68
Endocrine-disrupting chemicals use distinct mechanisms of action to modulate endocrine system function
###end article-title 68
###begin article-title 69
Xenoestrogen action in breast cancer: impact on ER-dependent transcription and mitogenesis
###end article-title 69
###begin article-title 70
The androgen receptor: structure, mutations, and antiandrogens
###end article-title 70
###begin article-title 71
Frequent loss of estrogen receptor-beta expression in prostate cancer
###end article-title 71
###begin article-title 72
Identifying biological themes within lists of genes with EASE
###end article-title 72
###begin article-title 73
Hormonal carcinogenesis and environmental influences: background and overview
###end article-title 73
###begin article-title 74
Estrogen receptor beta in prostate cancer
###end article-title 74
###begin article-title 75
###xml 76 81 <span type="species:ncbi:10090">mouse</span>
Estrogen receptor beta regulates epithelial cellular differentiation in the mouse ventral prostate
###end article-title 75
###begin article-title 76
Aberrant cellular retinol binding protein (CRBP1) gene expression and promoter methylation in prostate cancer
###end article-title 76
###begin article-title 77
###xml 56 61 <span type="species:ncbi:9606">human</span>
Frequent loss of estrogen and progesterone receptors in human prostatic tumors determined by quantitative real-time PCR
###end article-title 77
###begin article-title 78
Stage-specific characterization of the vascular endothelial growth factor axis in prostate cancer: expression of lymphangiogenic markers is associated with advanced-stage disease
###end article-title 78
###begin article-title 79
###xml 104 109 <span type="species:ncbi:9606">human</span>
Raloxifene, a mixed estrogen agonists/antagonists, induces apoptosis through cleavage of BAD in TSU-PR1 human cancer cells
###end article-title 79
###begin article-title 80
WISP3 (CCN6) is a secreted tumor-suppressor protein that modulates IGF signaling in inflammatory breast cancer
###end article-title 80
###begin article-title 81
###xml 20 28 <span type="species:ncbi:9606">patients</span>
Hormone therapy for patients with prostate carcinoma
###end article-title 81
###begin article-title 82
Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta
###end article-title 82
###begin article-title 83
Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta
###end article-title 83
###begin article-title 84
Metastasis of prostate cancer express estrogen receptor-beta
###end article-title 84
###begin article-title 85
Expression of estrogen receptor (ER)-alpha and ER-beta in normal and malignant prostatic epithelial cells: regulation by methylation and involvement in growth regulation
###end article-title 85
###begin article-title 86
###xml 97 102 <span type="species:ncbi:9606">human</span>
Comparative studies of the estrogen receptors beta and alpha and the androgen receptor in normal human prostate glands, dysplasia, and in primary and metastatic carcinoma
###end article-title 86
###begin article-title 87
Regulation of proliferation and production of prostate-specific antigen in androgen-sensitive prostatic cancer cells, LNCaP, by dihydrotestosterone
###end article-title 87
###begin article-title 88
Estrogen receptor (ER)-beta isoforms: a key to understanding ER-beta signaling
###end article-title 88
###begin article-title 89
Direct, androgen receptor-mediated regulation of the FKBP5 gene via a distal enhancer element
###end article-title 89
###begin article-title 90
Apigenin suppresses cancer cell growth through ERbeta
###end article-title 90
###begin article-title 91
Androgen receptor mutations in prostate cancer
###end article-title 91
###begin article-title 92
###xml 72 77 <span type="species:ncbi:9606">human</span>
Structural evidence for ligand specificity in the binding domain of the human androgen receptor. Implications for pathogenic gene mutations
###end article-title 92
###begin article-title 93
Essential role for estrogen receptor beta in stromal-epithelial regulation of prostatic hyperplasia
###end article-title 93
###begin article-title 94
Steroid-induced androgen receptor-oestradiol receptor beta-Src complex triggers prostate cancer cell proliferation
###end article-title 94
###begin article-title 95
Transition to androgen-independence in prostate cancer
###end article-title 95
###begin article-title 96
###xml 118 121 <span type="species:ncbi:10116">rat</span>
The selective estrogen receptor modulator trioxifene (LY133314) inhibits metastasis and extends survival in the PAIII rat prostatic carcinoma model
###end article-title 96
###begin article-title 97
###xml 250 255 <span type="species:ncbi:9606">human</span>
Effects of the environmental oestrogens bisphenol A, tetrachlorobisphenol A, tetrabromobisphenol A, 4-hydroxy-biphenyl and 4,4'-dihydroxybiphenyl on oestrogen receptor binding, cell proliferation and regulation of oestrogen sensitive proteins in the human breast cancer cell line MCF-7
###end article-title 97
###begin article-title 98
###xml 37 42 <span type="species:ncbi:9606">human</span>
Estrogen receptor beta expression in human prostate tissue
###end article-title 98
###begin article-title 99
Estrogen receptor beta (ERbeta) and inhibition of prostate cancer cell proliferation: studies on the possible mechanism of action in DU145 cells
###end article-title 99
###begin article-title 100
Antiandrogens in prostate cancer
###end article-title 100
###begin article-title 101
Microarray results improve significantly as hybridization approaches equilibrium
###end article-title 101
###begin article-title 102
Androgen-induced expression of endoplasmic reticulum (ER) stress response genes in prostate cancer cells
###end article-title 102
###begin article-title 103
Molecular determinants for the tissue specificity of SERMs
###end article-title 103
###begin article-title 104
Importance of dosage standardization for interpreting transcriptomal signature profiles: evidence from studies of xenoestrogens
###end article-title 104
###begin article-title 105
###xml 102 107 <span type="species:ncbi:9606">human</span>
Gene expression profiling reveals novel regulation by bisphenol-A in estrogen receptor-alpha-positive human cells
###end article-title 105
###begin article-title 106
Linear models and empirical bayes methods for assessing differential expression in microarray experiments
###end article-title 106
###begin article-title 107
###xml 62 67 <span type="species:ncbi:10090">mouse</span>
Bisphenol A exposure in utero disrupts early oogenesis in the mouse
###end article-title 107
###begin article-title 108
###xml 36 41 <span type="species:ncbi:9606">human</span>
Androgen receptor gene mutations in human prostate cancer
###end article-title 108
###begin article-title 109
Methylation of apoptosis related genes in the pathogenesis and prognosis of prostate cancer
###end article-title 109
###begin article-title 110
Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663
###end article-title 110
###begin article-title 111
The androgen receptor in prostate cancer
###end article-title 111
###begin article-title 112
Anti-androgens and the mutated androgen receptor of LNCaP cells: differential effects on binding affinity, heat-shock protein interaction, and transcription activation
###end article-title 112
###begin article-title 113
The androgen receptor in LNCaP cells contains a mutation in the ligand binding domain which affects steroid binding characteristics and response to antiandrogens
###end article-title 113
###begin article-title 114
###xml 68 73 <span type="species:ncbi:9606">human</span>
A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens
###end article-title 114
###begin article-title 115
A role for estrogen receptor beta in the regulation of growth of the ventral prostate
###end article-title 115
###begin article-title 116
Estrogen receptor beta in the prostate
###end article-title 116
###begin article-title 117
###xml 108 113 <span type="species:ncbi:9606">human</span>
Large effects from small exposures. III. Endocrine mechanisms mediating effects of bisphenol A at levels of human exposure
###end article-title 117
###begin article-title 118
Large effects from small exposures. I. Mechanisms for endocrine-disrupting chemicals with estrogenic activity
###end article-title 118
###begin article-title 119
Xenoestrogen action in prostate cancer: pleiotropic effects dependent on androgen receptor status
###end article-title 119
###begin article-title 120
Bisphenol A facilitates bypass of androgen ablation therapy in prostate cancer
###end article-title 120
###begin article-title 121
The xenoestrogen bisphenol A induces inappropriate androgen receptor activation and mitogenesis in prostatic adenocarcinoma cells
###end article-title 121
###begin article-title 122
Steroid 5 alpha-reductase 2 deficiency
###end article-title 122
###begin article-title 123
AP-2 regulates the transcription of estrogen receptor (ER)-beta by acting through a methylation hotspot of the 0N promoter in prostate cancer cells
###end article-title 123
###begin article-title 124
Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor
###end article-title 124
###begin article-title 125
Dynamic regulation of estrogen receptor-beta expression by DNA methylation during prostate cancer development and metastasis
###end article-title 125
###begin p 126
###xml 87 88 87 88 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</italic>
###xml 296 297 296 297 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</italic>
###xml 320 321 320 321 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</italic>
BPA induces androgen-independent cellular proliferation in cells expressing AR-T877A. (A) LNCaP cells were cultured under conditions of steroid hormone ablation (5% charcoal-/dextran-treated serum, CDT) and subsequently stimulated with either DHT, BPA, or vehicle control [0.1% ethanol (EtOH)]. (B) Cells cultured as in A were pulse labeled with BrdU for the last 16 hr of treatment, fixed, and BrdU incorporation was quantified by indirect immunofluorescence. Percent BrdU positive cells is shown. Error bars represent mean +/- SD.
###end p 126
###begin p 127
###xml 156 157 156 157 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 240 241 240 241 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</italic>
###xml 889 893 889 893 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KLK3</italic>
###xml 994 995 994 995 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</italic>
###xml 1078 1079 1078 1079 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</italic>
BPA induces a unique transcriptome in prostate cancer cells expressing AR-T877A. Microarray analyses were performed using triplicate biological replicates (n = 9) and statistical analyses performed as described in "Materials and Methods." (A) Heat map of the fold change estimates, averaged across sample, showing all genes with a statistically significant, > 2-fold alteration over vehicle control. Column 1 is statistically significant changes in averaged gene expression in BPA-treated samples compared with EtOH control; column 2 represents the statistically significant changes in expression after DHT relative to EtOH control. Column 3 is a comparative analysis and represents the genes that were statistically significant for BPA exposure compared with DHT treatments. Green bars indicate reduced expression, and red bars indicate induced gene expression. The bar representing PSA (KLK3) is indicated. Microarray experiment was performed on three independent experiments in triplicate. (B) VENN diagrams highlight the disparity in DHT and BPA effects on gene regulation. C) Gene Ontology was performed as described in "Materials and Methods." Categories passing statistical significance are shown. Gene annotations are from Unigene ().
###end p 127
###begin p 128
###xml 151 152 148 149 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</italic>
###xml 641 642 635 636 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</italic>
###xml 780 781 769 770 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 788 789 777 778 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 800 801 789 790 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 811 812 800 801 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</italic>
###xml 830 831 819 820 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
Validation of selected targets reveals that BPA significantly down-regulates ERbeta expression in cells expressing the BPA-responsive AR-T877A mutant. A) Validation of alterations in PSA expression was performed by RT-PCR. As expected, both DHT and BPA induced PSA expression in cells expressing AR-T877A (left panel). In agreement with the microarray, it was also noted that BPA induces down-regulation of ERbeta. By contrast, marked induction of WISP3 was also noted, and no effect was observed with FKBP5 (right panel). Numbers correspond to the band intensity of each sample set to EtOH (EtOH = 1) and relative to the GAPDH RNA control. B) The impact of BPA on ERbeta was quantified by real-time PCR, and relative copy number was determined. Error bars represent mean +/- SD; n = 9; *p < 0.05, **p < 0.01. (C) Representative (n = 3) immunoblot of ERbeta protein levels after BPA or DHT exposure. As shown, BPA exposure causes a marked reduction in ERbeta accumulation.
###end p 128
###begin p 129
###xml 261 262 255 256 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</italic>
###xml 288 289 282 283 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</italic>
Specificity of BPA-mediated modulation of ERbeta. ERbeta expression was monitored using at least two independent biological replicates for each condition and cell line, analyzed in triplicate and quantified by real-time PCR in cells expressing AR-H874Y (22Rv1, A) or wild-type AR (LAPC4, B). Error bars represent mean +/- SD.
###end p 129

